Almirall (ALM) Aandelenoverzicht
Almirall, S.A. is een biofarmaceutisch bedrijf dat zich richt op de gezondheid van de huid in Spanje, Europa, het Midden-Oosten, de Verenigde Staten, Azië en Afrika. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 5/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 3/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor ALM uit onze risicocontroles.
ALM Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Almirall, S.A. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €10.46 |
| 52 Week Hoogtepunt | €13.98 |
| 52 Week Laag | €10.24 |
| Bèta | 0.17 |
| 1 maand verandering | -6.61% |
| 3 maanden verandering | -11.05% |
| 1 Jaar Verandering | -6.61% |
| 3 jaar verandering | 9.93% |
| 5 jaar verandering | -25.87% |
| Verandering sinds IPO | -30.27% |
Recent nieuws en updates
ALM: Dermatology Pipeline Progress Will Drive Future Upside Repricing
Analysts have adjusted the Almirall price target to about €17.50 from about €16.57, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts covering Almirall are using a range of sector signals to frame their updated views, even when those signals come from different parts of the market.
ALM: Future Re-Rating Will Rely On Dermatology Pipeline And R&D Partnerships
Analysts have lifted their fair value estimate for Almirall to €14.58 from €13.91, reflecting updated assumptions for revenue growth, profit margins and a slightly lower discount rate. Together, these factors support a modestly higher long term price target and a marginally lower future P/E multiple.Recent updates
ALM: Dermatology Pipeline Progress Will Drive Future Upside Repricing
Analysts have adjusted the Almirall price target to about €17.50 from about €16.57, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts covering Almirall are using a range of sector signals to frame their updated views, even when those signals come from different parts of the market.ALM: Future Re-Rating Will Rely On Dermatology Pipeline And R&D Partnerships
Analysts have lifted their fair value estimate for Almirall to €14.58 from €13.91, reflecting updated assumptions for revenue growth, profit margins and a slightly lower discount rate. Together, these factors support a modestly higher long term price target and a marginally lower future P/E multiple.ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have nudged their price target on Almirall higher to €13.91 from €13.69, reflecting updated assumptions on revenue growth, profit margins and future P/E, despite a recent downgrade in stance from BNP Paribas. Analyst Commentary Analysts are sending mixed signals on Almirall, with a higher price target sitting alongside a more cautious rating.ALM: Future Re-Rating Will Rely On Dermatology Pipeline And Execution
Analysts slightly trimmed their price target for Almirall to €13.69 from €13.86, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Almirall plans to start a phase III study in the first half of 2026 evaluating Lebrikizumab (Ebglyss) for nummular eczema.ALM: Future Re-Rating Will Depend On Pipeline Execution And Ebglyss Ramp-Up
Narrative update on Almirall Analysts have raised their price target on Almirall to €14.50, citing what they see as a still-compelling valuation, along with expectations for Ebglyss ramp-up, upcoming clinical readouts, and potential in-licensing and M&A to support the mid-stage pipeline. Analyst Commentary Recent research points to a target price of €14.50 for Almirall, with the view that the shares still offer a compelling entry point despite a prior rebound in the stock.ALM: Future Re-Rating Will Hinge On Ebglyss Uptake And Pipeline Delivery
Analysts have modestly raised their price target on Almirall to EUR 14.50, citing expectations for a continued valuation re-rating supported by the ramp up of Ebglyss, upcoming clinical readouts, and potential in-licensing and M&A to bolster the mid-stage pipeline. Analyst Commentary Analyst views on Almirall remain broadly positive, with recent coverage highlighting both upside drivers and execution risks as the company advances its dermatology portfolio.Market Cool On Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 2.6x is worth a...ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have modestly raised their 12 month price target for Almirall to EUR 14.50, citing expectations that a continued re rating driven by Ebglyss ramp up, upcoming clinical readouts, and potential in licensing and M&A could support upside from current levels. Analyst Commentary Analysts note that Almirall's investment case is increasingly driven by visible growth levers in medical dermatology, but also caution that execution on product ramps and pipeline milestones will be critical to sustaining the recent share price rebound.ALM: Pipeline Milestones And Product Launch Momentum Will Drive Re-Rating
Analysts have increased their price target for Almirall from €13.30 to €13.87. They cite a compelling valuation, strong pipeline prospects, and expectations for continued growth driven by product launches and strategic developments.Almirall's (BME:ALM) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Almirall, S.A.'s ( BME:ALM ) stock...Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a good week for Almirall, S.A. ( BME:ALM ) shareholders, because the company has just released its latest...We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...The Almirall, S.A. (BME:ALM) Interim Results Are Out And Analysts Have Published New Forecasts
Almirall, S.A. ( BME:ALM ) came out with its interim results last week, and we wanted to see how the business is...European Demographics Will Drive Advancements In Dermatology Treatments
Strong specialty product launches and robust R&D pipeline are expected to drive growth, improve margins, and boost Almirall's market position in innovative dermatology.Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 44% Above Its Share Price
Key Insights The projected fair value for Almirall is €14.08 based on 2 Stage Free Cash Flow to Equity Current share...Why We're Not Concerned About Almirall, S.A.'s (BME:ALM) Share Price
With a median price-to-sales (or "P/S") ratio of close to 2.2x in the Pharmaceuticals industry in Spain, you could be...Statutory Profit Doesn't Reflect How Good Almirall's (BME:ALM) Earnings Are
Almirall, S.A. ( BME:ALM ) recently posted some strong earnings, and the market responded positively. Our analysis...These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Almirall, S.A. ( BME:ALM ) shareholders are probably feeling a little disappointed, since its shares fell 2.9% to €8.52...Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)
You may think that with a price-to-sales (or "P/S") ratio of 2x Almirall, S.A. ( BME:ALM ) is a stock worth checking...Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Almirall fair value estimate is €18.31 Current share price of...Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?
Key Insights Almirall's estimated fair value is €11.86 based on 2 Stage Free Cash Flow to Equity Almirall's €9.37 share...We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Rendement voor aandeelhouders
| ALM | ES Pharmaceuticals | ES Markt | |
|---|---|---|---|
| 7D | -0.2% | 1.5% | -0.6% |
| 1Y | -6.6% | 0.6% | 26.8% |
Rendement versus industrie: ALM presteerde slechter dan de Spanish Pharmaceuticals -sector, die het afgelopen jaar een rendement van 0.6 % opleverde.
Rendement versus markt: ALM presteerde slechter dan Spanish Market, dat het afgelopen jaar een rendement van 26.8 % opleverde.
Prijsvolatiliteit
| ALM volatility | |
|---|---|
| ALM Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 2.5% |
| Market Average Movement | 3.0% |
| 10% most volatile stocks in ES Market | 6.3% |
| 10% least volatile stocks in ES Market | 0.6% |
Stabiele aandelenkoers: ALM heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Spanish markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van ALM is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1943 | 2,097 | Carlos Gallardo Piqué | www.almirall.com |
Almirall, S.A. is een biofarmaceutisch bedrijf dat zich richt op huidgezondheid in Spanje, Europa, het Midden-Oosten, de Verenigde Staten, Azië en Afrika. Het bedrijf biedt zijn producten aan voor huidaandoeningen zoals psoriasis, atopische dermatitis, acne, actinische keratose, onychomycose, androgene alopecia, oncodermatologie en weesindicaties, alsook voor het spijsverteringskanaal en metabolisme; anti-infectiva voor systemisch gebruik; cardiovasculair, musculoskeletaal, zenuwstelsel en ademhalingssysteem; dermatologie; genito-urinair systeem en geslachtshormonen; immunostimulantia; metabolisme; en systematische hormonale preparaten. Het bedrijf heeft een samenwerking met Etherna voor het onderzoek naar en de ontwikkeling van op mRNA gebaseerde therapieën voor medische dermatologie.
Almirall, S.A. Samenvatting
| ALM fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €2.28b |
| Inkomsten(TTM) | €59.13m |
| Inkomsten(TTM) | €1.16b |
Is ALM overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ALM resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €1.16b |
| Kosten van inkomsten | €265.62m |
| Brutowinst | €891.17m |
| Overige uitgaven | €832.04m |
| Inkomsten | €59.13m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
Nov 09, 2026
| Winst per aandeel (EPS) | 0.27 |
| Brutomarge | 77.04% |
| Nettowinstmarge | 5.11% |
| Schuld/Eigen Vermogen Verhouding | 21.2% |
Hoe presteerde ALM op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/23 10:50 |
| Aandelenkoers aan het einde van de dag | 2026/08/21 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Almirall, S.A. wordt gevolgd door 28 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Luis Arredondo | Banco de Sabadell. S.A. |
| null null | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |